Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of AK112 Combined With Irinotecan Liposome in Patients With SCLC Who Progressed on Immune Checkpoint Inhibitors and Chemotherapy.

NCT06478043 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT06478043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06478043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of AK112 Combined With Irinotecan Liposome in Patients With SCLC Who Progressed on Immune Checkpoint Inhibitors and Chemotherapy.
Lead sponsor
Zhejiang Cancer Hospital
Phase
Phase 2
Overall status
Completed
Start date
October 16, 2024
Completion date
June 30, 2026
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small-cell lung cancer